{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T10:41:19Z","timestamp":1788777679630,"version":"build-2803163510"},"reference-count":9,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2016,4,4]],"date-time":"2016-04-04T00:00:00Z","timestamp":1459728000000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Birth Defects Research Pt B"],"published-print":{"date-parts":[[2016,4]]},"abstract":"<jats:p>Pregabalin was evaluated for potential developmental toxicity in mice and rabbits. Pregabalin was administered once daily by oral gavage to female albino mice (500, 1250, or 2500 mg\/kg) and New Zealand White rabbits (250, 500, or 1250 mg\/kg) during organogenesis (gestation day 6 through 15 [mice] or 6 through 20 [rabbits]). Fetuses were evaluated for viability, growth, and morphological development. Pregabalin administration to mice did not induce maternal or developmental toxicity at doses up to 2500 mg\/kg, which was associated with a maternal plasma exposure (AUC<jats:sub>0\u201324<\/jats:sub>) of 3790 \u03bcg\u2022hr\/ml, \u226530 times the expected human exposure at the maximum recommended daily dose (MRD; 600 mg\/day). In rabbits, treatment\u2010related clinical signs occurred at all doses (AUC<jats:sub>0\u201324<\/jats:sub> of 1397, 2023, and 4803 \u03bcg\u2022hr\/ml at 250, 500, and 1250 mg\/kg, respectively). Maternal toxicity was evident at all doses and included ataxia, hypoactivity, and cool to touch. In addition, abortion and females euthanized moribund with total resorption occurred at 1250 mg\/kg. There were no treatment\u2010related malformations at any dose. At 1250 mg\/kg, compared with study and historical controls, the percentage of fetuses with retarded ossification was significantly increased and the mean number of ossification sites was decreased, which correlated with decreased fetal and placental weights, consistent with in utero growth retardation. Therefore, the no\u2010effect dose for developmental toxicity in rabbits was 500 mg\/kg, which produced systemic exposure approximately 16\u2010times human exposure at the MRD. These findings indicate that pregabalin, at the highest dose tested, was not teratogenic in mice or rabbits<\/jats:p>","DOI":"10.1002\/bdrb.21174","type":"journal-article","created":{"date-parts":[[2016,4,4]],"date-time":"2016-04-04T21:11:45Z","timestamp":1459804305000},"page":"85-93","source":"Crossref","is-referenced-by-count":19,"title":["Embryo\u2010Fetal Developmental Toxicity Studies with Pregabalin in Mice and Rabbits"],"prefix":"10.1002","volume":"107","author":[{"given":"Dennis C.","family":"Morse","sequence":"first","affiliation":[{"name":"Pfizer Worldwide Research and Development Drug Safety Research and Development  Groton Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,4,4]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.reprotox.2007.12.001"},{"issue":"10","key":"e_1_2_8_3_1","first-page":"1065","article-title":"Teratogenic effects of pregabalin in mice","volume":"16","author":"Etemad L","year":"2013","journal-title":"Iran J Basic Med Sci"},{"key":"e_1_2_8_4_1","unstructured":"1988 US Food and Drug Administration Washington DC FDA Good laboratory practice regulations for nonclinical laboratory studies. Code of federal regulations (CFR) (April 1)"},{"key":"e_1_2_8_5_1","unstructured":"ICH.1993. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. Detection of toxicity to reproduction for medicinal products.http:\/\/www.ich.org\/home.html."},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdrb.21175"},{"key":"e_1_2_8_7_1","volume-title":"Guide for the care and use of laboratory animals. NIH Publication","author":"National Institutes of Health","year":"1985"},{"key":"e_1_2_8_8_1","unstructured":"Pfizer.2013. LYRICA\u00ae US prescribing information. Pfizer."},{"key":"e_1_2_8_9_1","unstructured":"Pfizer.2015. LYRICA\u00ae EU summary of product characteristics. Pfizer."},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2013.04.001"}],"container-title":["Birth Defects Research Part B: Developmental and Reproductive Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbdrb.21174","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbdrb.21174","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bdrb.21174","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/bdrb.21174","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bdrb.21174","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T03:24:17Z","timestamp":1694402657000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/bdrb.21174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":9,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["10.1002\/bdrb.21174"],"URL":"https:\/\/doi.org\/10.1002\/bdrb.21174","archive":["Portico"],"relation":{},"ISSN":["1542-9733","1542-9741"],"issn-type":[{"value":"1542-9733","type":"print"},{"value":"1542-9741","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4]]}}}